WahieSMeggittSJ. Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus. Br J Dermatol2013; 169: 653–659.
2.
ChassetFArnaudLJachietM, et al.Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol2018; 78: 107–114 e1.
3.
FrancesCCosnesADuhautP, et al.Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol2012; 148: 479–484.
4.
Costedoat-ChalumeauNAmouraZHulotJS, et al.Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 3284–3290.
5.
ArnaudLZahrNCostedoat-ChalumeauNAmouraZ. The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev2011; 10: 674–678.
6.
Costedoat-ChalumeauNHoussiauFIzmirlyP, et al.A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther2018; 103: 1074–1082.
7.
JallouliMGalicierLZahrN, et al.Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheum2015; 67: 2176–2184.
8.
KansalATripathiDRaiMKAgarwalV. Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus. Clin Rheumatol2016; 35: 341–349.
9.
TsujimuraSTanakaY. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol2012; 16: 102–108.
10.
van SchalkwykDAEganTJ. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist Update2006; 9: 211–226.
11.
Yeon LeeJLeeJKi KwokSHyeon JuJSu ParkKParkSH. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken)2017; 69: 536–542.
12.
LeeJYVinayagamoorthyNHanK, et al.Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheum2016; 68: 184–190.
13.
WahieSDalyAKCordellHJ, et al.Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol2011; 131: 1981–1986.
14.
Dominguez-GutierrezPRCeribelliASatohMSobelESReevesWHChanEK. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther2014; 16: R23–R23.
